Ironwood Pharmaceuticals
IRWD
164 hedge funds and large institutions have $1.49B invested in Ironwood Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 61 increasing their positions, 36 reducing their positions, and 20 closing their positions.
69% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 36
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
31% more call options, than puts
Call options by funds: $7.83M | Put options by funds: $5.96M
8% more funds holding
Funds holding: 152 → 164 (+12)
7.38% more ownership
Funds ownership: 103.66% → 111.03% (+7.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
15% less capital invested
Capital invested by funds: $1.76B → $1.49B (-$273M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$54.4M |
| 2 |
MP
MFN Partners
Boston,
Massachusetts
|
+$14.6M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$13.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.1M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$9.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15.3M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.75M |
| 4 |
HM
HealthCor Management
New York
|
-$5.47M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
-$4.75M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MFP
176
Michael F. Price
| – | -$91K | -8,358 | Closed |
|
|
CIAS
177
Capital Investment Advisory Services
Raleigh,
North Carolina
| – | -$13K | -1,185 | Closed |
|
|
SPIA
178
Steward Partners Investment Advisory
New York
| – | -$2.43K | -250 | -99% |
|
|
TRCT
179
Tower Research Capital (TRC)
New York
| – | -$2K | -185 | Closed |
|
180
Group One Trading
Chicago,
Illinois
| – | -$1.07K | -110 | Closed |
|
|
PA
181
Parallel Advisors
San Francisco,
California
| – | -$1K | -108 | Closed |
|
|
PCP
182
Proficio Capital Partners
Newton,
Massachusetts
| – | -$1K | -83 | Closed |
|
|
GAM
183
Gemmer Asset Management
Walnut Creek,
California
| – | +$29 | +3 | New |
|
|
PCG
184
Private Capital Group
West Hartford,
Connecticut
| – | +$437 | +45 | New |
|
IRWD Hedge Fund Activity: Q3 2019 in Review
164 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q3 2019, worth a combined $1.49B — down 15% from $1.76B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new IRWD positions and 20 closed out — a net gain of 13 holders — while 61 added to existing stakes and 36 trimmed.
The largest buyer was Brown Capital Management, adding an estimated $54.4M. The largest seller was Fidelity Investments, cutting an estimated $23.4M.
- 164 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q3 2019, up from 152 in Q2 2019.
- Funds reported $1.49B of Ironwood Pharmaceuticals stock for Q3 2019, down 15% quarter-over-quarter.
- 33 funds opened new Ironwood Pharmaceuticals positions in Q3 2019 and 20 closed out, a net change of +13 holders.
- The largest Ironwood Pharmaceuticals buyer in Q3 2019 was Brown Capital Management, an estimated $54.4M added.
- The largest Ironwood Pharmaceuticals seller in Q3 2019 was Fidelity Investments, an estimated $23.4M sold.
Based on aggregated 13F filings for Q3 2019.